Phoenix Biotech retweeted
❗ 폴란드 정부의 허위 정보 ❗
크라쿠프 테러범은 극우가 아니라 좌파였습니다!
페이스북 프로필이 차단되기 전에 직접 들어가 봤습니다.
프로필 내용으로 보면 오히려 공산주의와 LGBT+에 호의적이었던 것으로 보입니다. 기독교인들과 교황 요한 바오로 2세를 모욕하기도 했습니다.
Phoenix Biotech retweeted
$PGEN reminds me of how $XERS developed. It has a highly profitable product in a substantial market that has hardly been touched, plus a pipeline in several big markets. The market panicked because of potential competition that is unlikely to have any meaningful impact. European approval is very likely soon, along with new indications. It will take time and there is no immediate catalyts but i foresee this being a major position like XERS as it evolves. It looks like some support is devleoping but still very early.
Phoenix Biotech retweeted
Yep, $INO just diluted shares over 50% & now near a buck. I recall $PGEN being under a buck end of '24, but they had more of a glowing future and NO competition going forward, and still have no competition!....ha.
And Precigen still has a huge pipeline, and other entities owned.
Phoenix Biotech retweeted
bought $PGEN on the pull back and analyst reiterations
Phoenix Biotech retweeted
$INO $70m offering at 1.05 before discount, ripping off shareholders again, esp. naive new retail investors who bought it on FDA approval. i only see it will bleed faster and dilute more before seeing any revenue. this 70m will be gone even the confirmatory trial starts.
Phoenix Biotech retweeted
"Novartis has received 9 reports of tumors in patients previously treated with Zolgensma. Of those, two cases to date have shown evidence of vector DNA integration into the DNA of the patients."
sma-europe.eu/news/informati…
Almost certain better to have a tumor than SMA.
Sorry to add to the bad news today…
Novartis $NVS cites cases of previously unknown tumors possibly tied to its SMA gene therapy statnews.com/2026/11/05/nova… via @Jasonmmast @pharmalot
HCW $XERS Growth Across the Portfolio Accelerates, XP-8121 Adds
Significant Upside; Raise PT to $18 from $10
Phoenix Biotech retweeted
“That’s complete BS,” said Jeff Leiden, executive chairman of Vertex Pharmaceuticals , recalling a recent conversation with a tech leader who claimed AI would cure 90% of human disease in the next seven years.
Vertex has used roughly 50 AI companies to comb through its data set of 10,000 drug compounds, Leiden said. Not one managed to generate a working drug.
wsj.com/tech/ai/silicon-vall…
Phoenix Biotech retweeted
Fund redemption chatter heavy today, including at least one with significant biotech exposure.
